olivLaw · US equity research
Hims & Hers Health, Inc. HIMS
Services-Offices & Clinics of Doctors of Medicine · SIC 8011 · Vertical: Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
Hims & Hers Health operates a consumer-first digital health and wellness platform offering telehealth consultations, prescription treatments and non-prescription products delivered online. The company is expanding quickly in the US and abroad, and in the second quarter of 2026 revenue grew 38% to 753.2 million USD.
At the close of 04 Nov 2026, Hims & Hers Health, Inc. (HIMS) stock was 26.66 USD (+3.74% on the day), with market capitalisation 0 USD, beta 2.59, 52-week range 14.52–43.73 USD. Latest reported quarter (Q2 2026): revenue of 753.2 m USD (+38.2% YoY), net income of -86.3 m USD (−303.0% YoY), diluted EPS -0.37 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 43.6
- weak (30–45)
- Bollinger (20, 2)
- 25.51 – 31.26
- in the lower half of the band · %B 0.20 · band width 20.2%
- SMA 50 / 200
- 28.66 / 26.95
- mixed trend
- MACD (12, 26, 9)
- -0.65 / -0.37
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −10.1% | −1.1% | −9.0 pp | — |
| 3 months | −15.8% | −0.5% | −15.3 pp | — |
| 6 months | −0.8% | +4.4% | −5.2 pp | — |
| Year to date | −17.9% | +12.3% | −30.2 pp | — |
| 1 year | −37.7% | +13.5% | −51.2 pp | −2.2% |
| 3 years | +311.4% | +76.4% | +235.0 pp | −57.3% |
| 5 years | +220.0% | +63.7% | +156.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 401.6 m | 481.1 m | 586.0 m | 544.8 m | 599.0 m | 617.8 m | 608.1 m | 753.2 m |
| Cost of revenue | 83.7 m | 111.6 m | 155.3 m | 128.6 m | 156.9 m | 173.4 m | 211.3 m | 272.4 m |
| Gross profit | 317.9 m | 369.5 m | 430.7 m | 416.2 m | 442.1 m | 444.4 m | 396.8 m | 480.8 m |
| Operating income | 22.4 m | 18.6 m | 57.9 m | 26.7 m | 11.8 m | 9.2 m | -78.3 m | -97.2 m |
| Depreciation & amortisation | 4.4 m ≈ | 6.1 m | 8.3 m | 10.5 m ≈ | 17.7 m ≈ | 18.1 m | 22.0 m | 29.5 m ≈ |
| Pre-tax income | 23.6 m | 22.3 m | 60.5 m | 32.9 m | 12.2 m | 18.4 m | -101.6 m | -92.6 m |
| Income tax | -52.0 m | -3.7 m | 11.0 m | -9.7 m | -3.6 m | -2.2 m | -9.4 m | -6.3 m |
| Net income | 75.6 m | 26.0 m | 49.5 m | 42.5 m | 15.8 m | 20.6 m | -92.1 m | -86.3 m |
| Diluted EPS | 0.32 | 0.11 ≈ | 0.20 | 0.17 | 0.06 | 0.08 ≈ | -0.40 | -0.37 |
| Operating cash flow | 85.3 m ≈ | 86.4 m | 109.1 m | -19.1 m ≈ | 148.7 m ≈ | 61.3 m | 89.4 m | -35.9 m ≈ |
| Capex | 5.9 m | 26.9 m | 59.0 m | 50.4 m | 69.4 m | 63.9 m | 36.3 m | 32.3 m |
| Share repurchases | 30.0 m ≈ | 5.0 m | 0 | 0 ≈ | 9.5 m ≈ | 80.5 m | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 82.6 m | 148.8 m | 271.9 m | 526.9 m | 872.0 m | 1.5 bn | 2.3 bn |
| Revenue YoY | unavailable | +80.2% | +82.8% | +93.8% | +65.5% | +69.3% | +59.0% |
| Net income | -72.1 m | -18.1 m | -107.7 m | -65.7 m | -23.5 m | 126.0 m | 128.4 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | +1.8% |
| Diluted EPS | -2.07 | -0.51 | -0.58 | -0.32 | -0.11 | 0.53 | 0.51 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | −3.8% |
| net % | -87.3% | -12.2% | -39.6% | -12.5% | -2.7% | 8.5% | 5.5% |
| Free cash flow | unavailable | unavailable | unavailable | -33.7 m | 47.0 m | 198.3 m | 57.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 228.6 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 540.9 m USD
- Total assets
- 2.2 bn USD
- Debt / equity
- unavailable
- Current ratio
- 1.90x
- ROE
- 25.2%
- ROA
- 9.0%
- FCF margin
- 2.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 148.8 m | 271.9 m | 526.9 m | 872.0 m | 1.5 bn | 2.3 bn | SEC (XBRL)· 23 Feb 2026verified |
| Cost of revenue | 39.3 m | 67.4 m | 118.2 m | 157.1 m | 303.4 m | 614.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Gross profit | 109.5 m | 204.5 m | 408.7 m | 714.9 m | 1.2 bn | 1.7 bn | SEC (XBRL)· 23 Feb 2026verified |
| SG&A | 65.6 m | 183.6 m | — | — | — | — | SEC (XBRL)· 24 Feb 2022verified |
| Operating income | -15.1 m | -115.0 m | -68.7 m | -29.5 m | 61.9 m | 105.6 m | SEC (XBRL)· 23 Feb 2026verified |
| Depreciation & amortisation | 1.1 m | 4.1 m | 7.5 m | 9.5 m | 17.1 m | 54.5 m | SEC (XBRL)· 23 Feb 2026verified |
| EBITDA | -14.1 m ≈ | -111.0 m ≈ | -61.2 m ≈ | -19.9 m ≈ | 79.0 m ≈ | 160.1 m ≈ | SEC (XBRL)· 23 Feb 2026derived |
| Interest expense | 10.0 k | 0 | — | — | — | — | SEC (XBRL)· 24 Feb 2022verified |
| Pre-tax income | -18.0 m | -110.8 m | -65.7 m | -21.6 m | 71.7 m | 123.9 m | SEC (XBRL)· 23 Feb 2026verified |
| Income tax | 127.0 k | -3.1 m | -31.0 k | 2.0 m | -54.3 m | -4.4 m | SEC (XBRL)· 23 Feb 2026verified |
| Net income | -18.1 m | -107.7 m | -65.7 m | -23.5 m | 126.0 m | 128.4 m | SEC (XBRL)· 23 Feb 2026verified |
| Diluted EPS | -0.51 | -0.58 | -0.32 | -0.11 | 0.53 | 0.51 | SEC (XBRL)· 23 Feb 2026verified |
| Weighted average diluted shares | 35.4 m | 186.8 m | 204.5 m | 209.3 m | 236.8 m | 258.2 m | SEC (XBRL)· 23 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 27.3 m | 71.8 m | 46.8 m | 96.7 m | 220.6 m | 228.6 m | SEC (XBRL)· 23 Feb 2026verified |
| Receivables | 1.1 m | 4.1 m | 3.9 m | 6.7 m | 6.1 m | 32.1 m | SEC (XBRL)· 23 Feb 2026verified |
| Inventories | 3.5 m | 13.6 m | 21.6 m | 22.5 m | 64.4 m | 80.1 m | SEC (XBRL)· 23 Feb 2026verified |
| Current assets | 113.1 m | 269.9 m | 216.6 m | 265.1 m | 395.8 m | 767.6 m | SEC (XBRL)· 23 Feb 2026verified |
| Property, plant & equipment, net | 1.7 m | 2.2 m | 3.0 m | — | — | — | SEC (XBRL)· 27 Feb 2023verified |
| Goodwill | 0 | 110.9 m | 110.9 m | 110.9 m | 112.7 m | 278.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Intangibles (excl. goodwill) | 59.0 k | 25.9 m | 21.8 m | 18.6 m | 43.4 m | 196.1 m | SEC (XBRL)· 23 Feb 2026verified |
| Total assets | 118.7 m | 420.6 m | 366.3 m | 441.2 m | 707.5 m | 2.2 bn | SEC (XBRL)· 23 Feb 2026verified |
| Accounts payable | 8.1 m | 19.6 m | 32.4 m | 43.1 m | 91.2 m | 143.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Current liabilities | 15.2 m | 79.2 m | 47.9 m | 88.5 m | 221.4 m | 404.4 m | SEC (XBRL)· 23 Feb 2026verified |
| Total liabilities | 15.6 m | 86.0 m | 54.6 m | 97.2 m | 230.8 m | 1.6 bn | SEC (XBRL)· 23 Feb 2026verified |
| Equity | -146.9 m † | 334.6 m † | 311.7 m † | 344.0 m † | 476.7 m † | 540.9 m † | SEC (XBRL)· 23 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.5 m | -34.4 m | -26.5 m | 73.5 m | 251.1 m | 300.0 m | SEC (XBRL)· 23 Feb 2026verified |
| Capex | — | — | 7.2 m | 26.5 m | 52.8 m | 242.6 m | SEC (XBRL)· 23 Feb 2026verified |
| Free cash flow | — | — | -33.7 m ≈ | 47.0 m ≈ | 198.3 m ≈ | 57.4 m ≈ | SEC (XBRL)· 23 Feb 2026derived |
| Investing cash flow | -39.7 m | -156.3 m | 34.7 m | -12.1 m | -19.0 m | -1.0 bn | SEC (XBRL)· 23 Feb 2026verified |
| Financing cash flow | 47.7 m | 235.0 m | -33.1 m | -11.5 m | -107.8 m | 729.6 m | SEC (XBRL)· 23 Feb 2026verified |
| Share repurchases | 0 | 0 | 0 | 2.0 m | 83.0 m | 90.0 m | SEC (XBRL)· 23 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 18.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 0 USD
Key indicators
Coverage and freshness
Score by group
19% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -5.5% | 63 (vs peers) | 33% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 64.5% | 100 (on a fixed band) | 44% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 0.9x | 11 (on a fixed band) | 22% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial11/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial63/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
HIMS & HERS HEALTH, INC. (HIMS). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 2.3 bn USD in 2025; YoY growth 59.0%; net margin -5.5%; ROE -32.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 64.5%
What contradicts it
- Current ratio: 0.9x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Offices & Clinics of Doctors of Medicine (SIC 8011) · same industry (4-digit SIC) · compared with 8 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TDOCTeladoc Health, Inc. | 1.8 bn | — | -11.5% | -6.3% | −1.5% | +28% / −47% |
| STLNStarling Oncology, Inc. | 707.3 m | — | — | -6.2% | +27.8% | +121% / +306% |
| SBCSBC Medical Group Holdings Incorporated | 547.1 m | 11.4 | 19.3% | 28.0% | −15.5% | +49% / −51% |
| CCMConcord Medical Services Holdings Ltd | 481.9 m | — | — | -20.2% | +25.2% | −4% / −63% |
| AIRSAirSculpt Technologies, Inc. | 122.6 m | — | -12.0% | -7.8% | −15.8% | −52% / −66% |
| LFMDLifeMD, Inc. | 118.1 m | — | 6.5% | 0.1% | +25.3% | −36% / −68% |
| BMGLBasel Medical Group Ltd | 8.2 m | — | -169.7% | -94.0% | unavailable | −64% / unavailable |
| AUNAAuna S.A. | — | — | 7.5% | 2.5% | +13.2% | 0% / unavailable |
| HIMSHims & Hers Health, Inc. | 0 | — | -32.0% | -5.5% | +59.0% | −38% / +311% |
1- and 3-year price returns: for HIMS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable |
| 3 years | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable |
| 5 years | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Hims & Hers Health operates a consumer-first digital health and wellness platform offering telehealth consultations, prescription treatments and non-prescription products delivered online. The company is expanding quickly in the US and abroad, and in the second quarter of 2026 revenue grew 38% to 753.2 million USD 3.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Regulationhigh
The company operates in a heavily regulated field where violations can bring penalties and restructuring 1.
- Profitabilityhigh
The net loss in the second quarter of 2026 shows that profitability is not assured 3.
- Acquisition integrationmedium
The Eucalyptus deal includes deferred payments and earn-outs, and integration could prove difficult 1.
- Supply chainmedium
Disruptions in supply could delay products or raise compliance costs 1.
- Data securitymedium
Sensitive health data makes the company exposed to attacks and legal liability 1.
Investment thesis
What would need to be true (bull case)
What to watch
- Third-quarter results and whether revenue guidance holdsQ3 2026
- Closing of the Eucalyptus acquisition and its effect on international revenuemid-2026
- Development of gross margin compared with the second quarter levelQ3 2026
- Regulatory changes affecting GLP-1 and compounded medicationsnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Hims & Hers describes its business as a consumer-first platform that connects patients with licensed healthcare professionals who can prescribe medication, with prescriptions fulfilled online through licensed pharmacies 1. Its offerings cover sexual health, hair loss, hormone health, weight loss, dermatology and mental health, plus laboratory testing and non-prescription wellness products, many sold on subscription 1. Total revenue for fiscal 2025 was 2347.6 million USD 1.
The operating model relies on Affiliated Medical Groups, physician-owned entities that employ providers and deliver services exclusively through the platform where corporate practice of medicine is prohibited. The company acts as their exclusive administrative services provider for non-clinical functions in exchange for a fixed fee 1. It also owns pharmacies, a 503B compounding facility, a peptide facility and a laboratory, which gives it control over supply 1.
The proposed acquisition of Eucalyptus, an Australia-based digital health company operating in Australia, the United Kingdom, Germany, Canada and Japan, extends international reach. It was expected to close in mid-2026, and the company later reported the close in June 2026 13.
Segments
Personalized offerings and the Hers brand
Personalized offerings, treatment plans developed by licensed providers, represented over 70% of US revenue in 2025, up from about half in 2024. The Hers brand accounted for nearly 40% of US revenue, and most US revenue came from non-GLP-1 offerings 1.
Market context
The company competes in digital health and wellness, where it measures its share by customer count and total sales using externally reported data 1. The US is its largest market, while expansion into Europe, Canada and Asia-Pacific opens new segments. Subscribers reached 2891 thousand at June 30, 2026 3.
Monthly revenue per average subscriber was 92 USD in the second quarter of 2026, up from 76 USD in 2025, suggesting better monetization of the customer base 3. The company has set a target of at least 6.5 billion USD in revenue by 2030 3.
Trends
- Expansion into new specialtiestailwind
The company launched offerings for testosterone, menopause and perimenopause and intends to add conditions such as sleep disorders, fertility or hypertension. If these specialties develop, they could support revenue growth 1.
- International expansionmixed
The Eucalyptus deal and operations in the United Kingdom, Germany and Canada could widen the customer base, but they bring deferred payments and earn-out terms tied to future performance 1.
- Pressure on gross marginheadwind
Gross margin fell to 64% in the second quarter of 2026 from 76% a year earlier, and the company reported a net loss, which could limit profitability if the trend continues 3.
- Regulation and GLP-1 supplyheadwind
GLP-1 medications face high demand, regulatory limits and constrained manufacturing capacity. Changes in rules could limit customers' access to these treatments 1.
Competitive position
The company says it faces competition from large established healthcare providers, traditional retailers, pharmaceutical companies and technology firms with significant resources 1. Its advantages rest on brand, technology and its provider network.
Through partnerships with health systems and UK retail platforms, the company aims to stay visible to customers beyond its own app 1. A tighter competitive field could press prices and customer acquisition costs.
- Traditional health systems
Providers of in-person medical care, named as rivals in the company's risk disclosures 1.
- Retail chains and pharmacies
Retailers with physical and online channels selling wellness products and medicines, named as potential rivals 1.
- Pharmaceutical companies
Manufacturers that could offer treatments directly to consumers, named as a source of competition 1.
- Large technology companies
Well-resourced technology firms active in digital health, named as competitors 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Hims & Hers Just Went Negative on Profit. Twice.Yahoo Finance — News · 22 Sept 2026 · EN
- Hims & Hers Chief Legal Officer Soleil Boughton Sells 6,236 SharesYahoo Finance — News · 19 Sept 2026 · EN
- Hims & Hers’ Australia Expansion Adds Growth, But Execution Will Be KeyYahoo Finance — News · 31 Aug 2026 · EN
- Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own CompanyYahoo Finance — News · 28 Aug 2026 · EN
- Hims & Hers (HIMS)’ Weight-Loss Plans Results Penalties Over Visa (V) Credit Card DisputesYahoo Finance — News · 28 Aug 2026 · EN
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It MattersYahoo Finance — News · 24 Aug 2026 · EN
- Hims & Hers accused of sharing health secrets and hiding the cancel buttonThe Register · 30 Jul 2026 · RO
The latest news item in our archive is from 22 Sept 2026; the newest SEC filing is from 07 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report07 Oct 2026Departure or appointment of officers
- Quarterly report10 Aug 2026
- Current report10 Aug 2026Results of operations · Financial statements and exhibits
- Current report17 Jul 2026Departure or appointment of officers
- Current report01 Jul 2026Material agreement · Creation of a direct financial obligation · Financial statements and exhibits
- Current report15 Jun 2026Shareholder vote
- Current report02 Jun 2026Material agreement · Creation of a direct financial obligation · Other events · Financial statements and exhibits
- Current report21 May 2026Material agreement · Creation of a direct financial obligation · Item 3.02 · Financial statements and exhibits
- Current report19 May 2026Other events · Financial statements and exhibits
- Quarterly report11 May 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Hims & Hers Health, Inc. · 23 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Hims & Hers Health, Inc. · 10 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Hims & Hers Health, Inc. · 10 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.